+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating TQB2102 for injection, a new antibody-coupled drug that targets two different parts of the HER2 protein on tumor cells. This study focuses on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. The trial aims to assess the effectiveness and safety of TQB2102 combined with benmelstobart or penpulimab, with or without chemotherapy, in this patient group. This is a Phase II randomized study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive TQB2102 for injection and either benmelstobart or penpulimab, both given intravenously every three weeks. Chemotherapy is taken orally from Day 1 to Day 15 in each 21-day treatment cycle. There are three study groups, each involving different combinations and doses of TQB2102, benmelstobart, penpulimab, and chemotherapy. Treatment continues through multiple cycles as determined by the study protocol. During the study, participants undergo regular assessments including scans and tests to measure tumor response and disease progression. Researchers monitor outcomes like the objective response rate, progression-free survival, duration of response, overall survival, and any adverse events. The study includes follow-up periods to track safety and effectiveness, with an average observation of up to three years. Participants are closely monitored throughout the treatment and follow-up phases for their health and response to therapy.

Age: 18Years - 75YearsAll GendersPhase 2
39 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
S

Actively Recruiting

Researchers are evaluating the effects of the medicine semaglutide on kidney and heart health in adults who have type 2 diabetes and chronic kidney disease. The study aims to understand how semaglutide, given as a weekly injection under the skin, affects these conditions and whether it is safe to use in this population. This is a Phase 4 clinical trial lasting about 60 to 172 weeks. Participants will receive semaglutide through a subcutaneous injection once every week. The study monitors the time to the first occurrence of significant kidney function decline, kidney failure, kidney-related death, or cardiovascular death. Secondary outcomes include changes in kidney function measures, urinary albumin levels, blood sugar control, cardiovascular events, and safety events such as severe low blood sugar episodes. Throughout the study, participants will be regularly assessed for kidney and heart function using laboratory tests like estimated glomerular filtration rate eGFR, urine albumin-to-creatinine ratio, and glycated hemoglobin HbA1c. Researchers will track serious adverse events and episodes of severe hypoglycemia. The study involves ongoing monitoring from baseline up to about 169 weeks, allowing detailed evaluation of both health outcomes and treatment safety.

Age: 18Years +All GendersPhase 4
26 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.

Age: 18Years +All GendersPhase 3
131 locations
E

Actively Recruiting

Researchers are studying the safety and effectiveness of TQB2102 for injection in patients with HER2-positive biliary tract cancer. This includes patients with locally advanced or metastatic forms of the disease who have experienced failure of 1-2 prior systemic therapies. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and spans phases 1 and 2 to evaluate dosing, safety, and immune response. Participants receive TQB2102, a HER2 dual-antibody-drug conjugate, by intravenous infusion every three weeks in cycles of 21 days. Treatment involves 6 to 8 cycles, with ongoing monitoring for adverse events and response to therapy. The study does not use masking or placebo controls. During the trial, participants undergo assessments for tumor response, disease control, survival, and side effects from the time of consent until 28 days after the last dose or the start of a new antitumor therapy. Follow-up includes evaluations up to 36 weeks for outcomes like progression-free and overall survival. Participants also provide tumor tissue samples for HER2 testing and are monitored for immune reactions and safety throughout the study.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
43 locations
P

Actively Recruiting

Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.

Age: 18Years +All GendersPhase 3
265 locations
S

Actively Recruiting

Researchers are investigating the effects and safety of the medicine PF-07275315 for treating moderate to severe Chronic Obstructive Pulmonary Disease COPD, a lung condition that makes breathing difficult and impacts daily life. This interventional study involves adults aged 35 to 80 who have had COPD for at least 12 months and experienced at least two moderate or severe exacerbations in the past year while on stable maintenance treatment. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections at the clinic. The Phase 2 portion lasts 24 weeks with study involvement totaling about 40 weeks and includes 11 clinic visits. The Phase 3 portion lasts 52 weeks with approximately 68 weeks total involvement and 18 clinic visits. The study compares outcomes between those receiving PF-07275315 and those receiving placebo to evaluate safety and effectiveness. During the study, participants will undergo regular assessments including lung function tests such as forced expiratory volume FEV1, monitoring of exacerbation rates, symptom questionnaires, safety lab tests, electrocardiograms, and vital signs. Safety and adverse events will be closely tracked throughout the study, and participants will be followed for the full duration of their assigned phase to monitor changes and outcomes related to COPD.

Age: 35Years - 80YearsAll GendersPhase 2Phase 3
189 locations
E

Actively Recruiting

This research aims to better understand the use of felzartamab in adults with primary membranous nephropathy PMN, a kidney condition where autoantibodies damage the kidneys filtering units, causing protein leakage into the urine and potential kidney failure. The study compares the effects of felzartamab, a laboratory-made antibody targeting immune cells, with tacrolimus, a commonly used drug for PMN treatment. Participants will be randomly assigned to receive either intravenous felzartamab infusions or oral tacrolimus tablets during the open-label treatment phase. Those who experience worsening kidney function, increased proteinuria, relapse, or no improvement may receive rescue treatments, including standard immunosuppressive therapy or additional felzartamab doses. The study includes an initial screening period lasting up to 42 days, followed by treatment phases and possible rescue therapy, with some participants followed for up to 156 weeks. Throughout the study, participants will attend up to 23 visits for monitoring and assessments. Researchers will measure how many achieve complete remission of proteinuria after 104 weeks, track kidney function stability, assess fatigue and physical health, and monitor safety and immune responses to felzartamab. Follow-up visits occur every 12 weeks if treatment stops early, ensuring continued evaluation until week 104 or beyond.

Age: 18Years - 80YearsAll GendersPhase 3
114 locations
C

Actively Recruiting

Researchers are comparing the effects and safety of two drugs, GQ1005 and Trastuzumab Emtansine T-DM1, in adults with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. This phase III trial focuses on patients who have previously been treated with trastuzumab and taxane. The study aims to understand which treatment might better manage this advanced form of breast cancer. Participants will be randomly assigned to receive either GQ1005 or T-DM1. Both drugs are given through intravenous infusions every 21 days. About 228 patients will take part, and the treatments will continue to be monitored over approximately 24 months to assess their impact on cancer progression and safety. During the study, participants will have regular assessments including scans to measure tumor size and blood tests to monitor the drugs in their system. Researchers will track how long patients live without cancer progression, overall survival, response rates, adverse events, and quality of life changes. These evaluations will help understand the benefits and risks of each treatment over time.

Age: 18Years - 75YearsAll GendersPhase 3
70 locations
S

Actively Recruiting

Hepatocellular carcinoma HCC is a serious cancer with high rates of illness and death. Surgery is the main treatment, but the cancer often returns, especially in patients with a high risk of recurrence after surgery. Researchers are studying how to lower the chance of cancer returning and improve survival, as there is currently no standard treatment after surgery. This study evaluates the safety and effectiveness of combining two drugs, donafenib and envafolimab, for patients at high risk of recurrent HCC after surgery. Participants will receive donafenib orally at 100mg twice daily and envafolimab intravenously at 300mg every three weeks. Treatment cycles range from 6 to 12 months or 8 to 16 sessions, continuing until cancer recurrence, unacceptable side effects, death, withdrawal, or completion of 16 envafolimab cycles. This is a single-arm, multicenter study designed to assess this drug combination as an adjuvant therapy after surgery. During the study, participants will be monitored for recurrence-free survival over 24 months. Researchers will also track overall survival, the rate of survival and recurrence at two years, and any adverse events during this time. Patients will undergo imaging and laboratory tests to confirm no cancer recurrence before starting treatment and will be followed closely throughout to assess treatment effects and safety.

Age: 18Years - 80YearsAll GendersPhase 2
2 locations

1-10 of 33

1